Eurogentec and OGT are pleased to announce the conclusion of a licence agreement. The acquired licence refers to OGT's "Southern array patents", fundamental patents covering the manufacture and use and marketing of oligonucleotide MicroArrays, and will remain valid for the patent's lifetime. Read press release: Here
Commenting on the agreement, Dr. Driss Talibi, DNA Array Product Manager at Eurogentec, said "We were in contact with OGT at the earliest stage to discuss the successful agreement, which further strengthens our position in the market segment of custom-made oligo-based MicroArrays". Jean-Pierre Delwart, CEO at Eurogentec, further added "The agreement is very important for our genomic oligo business and we believe that this licence will strongly contribute to increase our HTP oligo business".
Dr Mike Evans, Chief Executive of OGT, said: "We are happy to support Eurogentec's technology by granting this licence and thus further the use of MicroArray technology".